Evelo is a clinical-stage biotech with a vision to dramatically improve healthcare. Our work aims to harness SINTAX to modulate the body’s immune system.
Employees: 51-200
Total raised: $50M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | K2 HealthV... | k2healthve... |
| - | SV Health ... | svhealthin... |
| - | K2 HealthV... | k2hv.com |
| - | Horizon Te... | horizontec... |
| - | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.07.2017 | Series B | $50M | - |
Mentions in press and media 19
| Date | Title | Description |
| 20.08.2026 | Bacteria, Billions and Buzzwords: Is the Gut Microbiome Startup Boom Backed by Science? | Investors have bankrolled hundreds of millions of pounds into companies that claim they can decode the inner workings of your gut. Behind the personalised nutrition apps and at-home stool tests, as well as the pitch deck for the next genera... |
| 12.07.2023 | Evelo Biosciences Closes $25.5 Million Private Placement | - |
| 25.05.2022 | Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock | CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities... |
| 28.10.2021 | Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights - Form 8-K | Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights -Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies- -Dosing for Phase 2 EDP1815 Phase 2 trial in atopic derma... |
| 28.10.2021 | Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights | –Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies– –Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021– –Preclinical data support development of EDP1867 in neur... |
| 09.03.2021 | EVELO BIOSCIENCES, INC. Evelo Biosciences : Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights | –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b c... |
| 25.07.2019 | Evelo Biosciences Secures $45M Debt Financing from K2 HealthVentures | CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that i... |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!” If you spot someone wearing a tee shirt with that saying, there is some chance they work at a microbiome startup. If they don’t, it’s probably worth looking into. The human microbiome is a... |
| 09.05.2018 | Evelo Bio grabs $85M as the latest early-stage biotech debuts on Nasdaq | Evelo Biosciences became the latest early-stage biotech company to make the leap into Nasdaq. The Cambridge, MA-based company priced 5.3 million shares at $16 — smack dab in the middle of the range — to add $85 million to its ... |
| 14.04.2018 | Flagship’s Evelo Biosciences pitches $100M IPO for a new platform of monoclonal microbials | Simba Gill With its lead “monoclonal microbial” about to be tested for the first time on a human, Evelo Biosciences believes that this is the right time to float a $100 million IPO. Launched with $85.4 million raised from the sa... |
Show more